[1]田会凤.利培酮联合丙戊酸钠治疗精神分裂症攻击行为的效果及安全性[J].医学信息,2023,36(21):134-137.[doi:10.3969/j.issn.1006-1959.2023.21.031]
 TIAN Hui-feng.Effect and Safety of Risperidone Combined with Sodium Valproate in the Treatment of Aggressive Behavior of Schizophrenia[J].Journal of Medical Information,2023,36(21):134-137.[doi:10.3969/j.issn.1006-1959.2023.21.031]
点击复制

利培酮联合丙戊酸钠治疗精神分裂症攻击行为的效果及安全性()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年21期
页码:
134-137
栏目:
药物与临床
出版日期:
2023-11-01

文章信息/Info

Title:
Effect and Safety of Risperidone Combined with Sodium Valproate in the Treatment of Aggressive Behavior of Schizophrenia
文章编号:
1006-1959(2023)21-0134-04
作者:
田会凤
(天津建华医院精神康复二科,天津 300393)
Author(s):
TIAN Hui-feng
(The Second Department of Mental Rehabilitation,Tianjin Jianhua Hospital,Tianjin 300393,China)
关键词:
精神分裂症攻击行为利培酮丙戊酸钠生活质量
Keywords:
SchizophreniaAggressive behaviorRisperidoneSodium valproateQuality of Life
分类号:
R749.3
DOI:
10.3969/j.issn.1006-1959.2023.21.031
文献标志码:
A
摘要:
目的 探究利培酮联合丙戊酸钠治疗精神分裂症(SP)攻击行为的效果及安全性。方法 以2021年3月-2023年3月天津建华医院收治的100例精神分裂症患者为研究对象,经随机数字表法分为对照组(50例)与观察组(50例)。对照组给予利培酮治疗,观察组应用利培酮联合丙戊酸钠治疗,比较两组临床疗效、阳性和阴性症状量表(PANSS)、攻击行为[修订版外显攻击行为量表(MOAS)、精神病患者攻击感知量表(POPAS)]、精神分裂症患者生活质量量表(SQLS)评分及不良反应。结果 观察组总有效率高于对照组(P<0.05);两组治疗后PANSS评分低于治疗前,且观察组PANSS评分低于对照组(P<0.05);两组治疗后MOAS、POPAS评分低于治疗前,且观察组MOAS、POPAS评分低于对照组(P<0.05);两组治疗后SQLS评分均低于治疗前,且观察组SQLS评分均低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 利培酮联合丙戊酸钠治疗精神分裂症效果确切,可有效减轻患者精神症状,改善其攻击行为,且不增加药物不良反应,有助于患者生活质量的提升。
Abstract:
Objective To explore the effect and safety of risperidone combined with sodium valproate in the treatment of aggressive behavior of schizophrenia (SP).Methods A total of 100 patients with schizophrenia admitted to Tianjin Jianhua Hospital from March 2021 to March 2023 were divided into control group (50 patients) and observation group (50 patients) by random number table method. The control group was treated with risperidone, and the observation group was treated with risperidone combined with sodium valproate. The clinical efficacy, Positive and Negative Symptom Scale (PANSS), aggressive behavior [Modified Overt Aggression Scale (MOAS), Perception of Prevalence of Aggression Scale (POPAS)], Schizophrenia Quality of Life Scale (SQLS) score and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group (P<0.05). The PANSS score of the two groups after treatment was lower than that before treatment, and the PANSS score of the observation group was lower than that of the control group (P<0.05). The scores of MOAS and POPAS in the two groups after treatment were lower than those before treatment, and the scores of MOAS and POPAS in the observation group were lower than those in the control group (P<0.05). The SQLS scores of the two groups after treatment were lower than those before treatment, and the SQLS scores of the observation group were lower than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Risperidone combined with sodium valproate is effective in the treatment of schizophrenia, which can effectively reduce the mental symptoms of patients, improve their aggressive behavior, and do not increase adverse drug reactions. Meanwhile, it is helpful to improve the quality of life of patients.

参考文献/References:

[1]陈彩红,张伟宏,顾文谊.奥氮平联合利培酮治疗伴激越症状的精神分裂症的临床观察[J].贵州医药,2023,47(3):360-361.[2]史晗,赵晶媛,杨勇锋,等.阿立哌唑联合利培酮治疗对男性精神分裂症患者血清催乳素及糖脂代谢的影响[J].新乡医学院学报,2018,35(6):469-473.[3]刘邦文,张金伟,王建锋.利培酮联合脑电生物反馈对精神分裂症患者认知功能、日常行为能力及睡眠脑电活动的影响观察[J].川北医学院学报,2023,38(2):241-244,248.[4]裘建萍,陆峥,班春霞,等.利培酮联合不同剂量艾司西酞普兰对精神分裂症患者社会功能的影响[J].国际精神病学杂志,2022,49(3):436-439,450.[5]白金娟,田龙,张红利,等.丙戊酸钠联合利培酮治疗癫痫所致精神障碍的疗效观察[J].国际精神病学杂志,2019,46(1):130-133.[6]陈江.利培酮联合丙戊酸钠对精神分裂症患者认知功能的影响及疗效[J].上海医药,2021,42(14):20-22.[7]张锐,宫璇,肖玲,等.阿立哌唑联合利培酮对缓解精神分裂症患者暴力行为的影响[J].临床和实验医学杂志,2021,20(1):35-39.[8]崔彦龙,严保平,孙秀丽,等.氨磺必利与利培酮治疗阴性症状为主精神分裂症疗效及安全性对照研究[J].医学研究与教育,2018,35(6):42-47.[9]向伟,朱丽萍,陈妍,等.利培酮联合达营片对精神分裂症患者社会功能的影响[J].药学服务与研究,2019,19(3):213-215.[10]Luis G,José L,Andrés A,et al.Quality of life in schizophrenia: development, reliability and internal consistency of the Lancashire Quality of Life Profile – European Version: EPSILON Study 8[J].British Journal of Psychiatry,2018,177(39):49-54.[11]侯梦慧,刘晓林,陈飞飞,等.利培酮联合不同心境稳定剂治疗伴攻击行为精神分裂症的疗效[J].医学综述,2021,27(21):4342-4346.[12]李涛,李界兴,尚同军,等.奥氮平片与利培酮片治疗男性精神分裂症疗效、安全性及对患者生活质量影响对比研究[J].陕西医学杂志,2019,48(5):657-660.[13]丁木兵,宋传福,蔡昌群,等.利培酮维持治疗精神分裂症的疗效和安全性研究[J].药物生物技术,2020,27(5):433-437.[14]刘明秋,黄汉军.分析对比奥氮平与利培酮治疗老年精神分裂症的疗效及安全性[J].中国医院药学杂志,2018,38(15):1648-1651.[15]赵哲婷,徐方,陈磊,等.丙戊酸钠联合奥氮平治疗男性难治性精神分裂症效果及对认知功能、PRL、GH、Hcy影响[J].临床误诊误治,2022,35(8):44-47.[16]陈云郁,徐裕,汪芳军,等.利培酮联合丙戊酸钠对感染性脑炎致精神障碍患者MOAS和PAN-SS评分的影响[J].中华医院感染学杂志,2018,28(11):1666-1669.[17]张坤,刘杰.阿立哌唑与利培酮治疗精神分裂症疗效及安全性的对比研究[J].中国医院用药评价与分析,2018,18(5):621-623.[18]王飞,王婷,刘文丞,等.丙戊酸钠联合利培酮治疗感染性脑炎所致精神障碍伴攻击行为患者的疗效评价[J].医学临床研究,2021,38(12):1877-1879.[19]雒江妮,柏林,曹媛媛,等.丙戊酸钠联合利培酮对癫痫性精神障碍患者社会功能、精神症状的影响分析[J].中国国境卫生检疫杂志,2020,43(1):41-42,53.[20]周波,冯杰.利培酮联合阿立哌唑对慢性精神分裂症患者认知功能及社会功能的影响[J].医学临床研究,2019,36(8):1533-1535.

相似文献/References:

[1]邹超杰,程宇琪.肠道微生物在精神分裂症中的研究进展[J].医学信息,2018,31(02):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
 ZOU Chao-jie,CHENG Yu-qi.Progress in the Study of Intestinal Microorganism in Schizophrenia[J].Journal of Medical Information,2018,31(21):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
[2]张 健,江 芮.生活技能训练对精神分裂症缓解期患者日常生活能力的影响[J].医学信息,2018,31(03):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
 ZHANG Jian,JIANG Rui.Effect of Life Skills Training on Daily Living Ability of Patients with Schizophrenia in Remission Staged[J].Journal of Medical Information,2018,31(21):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
[3]沈雪梅.齐拉西酮与奥氮平治疗首发精神分裂症 疗效及糖脂代谢的影响观察[J].医学信息,2018,31(06):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
 SHEN XUE-mei.The Effect of Ziprasidone and Olanzapine in the Treatment of First Episode Schizophrenia and the Effect of Glycolipid Metabolism[J].Journal of Medical Information,2018,31(21):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
[4]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
 CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Journal of Medical Information,2018,31(21):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
[5]孙占娟.精神分裂症患者的认知康复治疗进展[J].医学信息,2018,31(13):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
 SUN Zhan-juan.Progress in Cognitive Rehabilitation Therapy of Schizophrenia Patients[J].Journal of Medical Information,2018,31(21):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
[6]吴金丽.阿立哌唑的临床应用[J].医学信息,2018,31(14):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
 WU Jin-li.Clinical Application of Aripiprazole[J].Journal of Medical Information,2018,31(21):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
[7]宋典雄.激励理论指导下的护理干预对精神分裂症患者的影响[J].医学信息,2018,31(18):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
 SONG Dian-xiong.The Effect of Nursing Intervention under the Guidance of Motivation Theory on Patients with Schizophrenia[J].Journal of Medical Information,2018,31(21):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
[8]凌 梅,刘静芳.精神分裂症患者研究伙伴的相关研究进展[J].医学信息,2018,31(19):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
 LING Mei,LIU Jing-fang.Progress in Research on Research Partners in Patients with Schizophrenia[J].Journal of Medical Information,2018,31(21):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
[9]韩佳睿,张 苹,张 媛.迟发性运动障碍与DNA甲基化之间关系的研究进展[J].医学信息,2018,31(20):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
 HAN Jia-rui,ZHANG Ping,ZHANG Yuan.Advances in Research on the Relationship between Tardive Dyskinesia and DNA Methylation[J].Journal of Medical Information,2018,31(21):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
[10]陈宽玉,孔 骞,黄玉桃.首发缓解期精神分裂症患者日常生活模式的调查[J].医学信息,2019,32(04):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
 CHEN Kuan-yu,KONG Qian,HUANG Yu-tao.Investigation on the Daily Life Pattern of Patients with Schizophrenia in the First Remission Period[J].Journal of Medical Information,2019,32(21):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
[11]倪 珂,李 磊,回佳印,等.精神分裂症患者外周血miR-21表达水平与攻击行为的相关性研究[J].医学信息,2023,36(02):65.[doi:10.3969/j.issn.1006-1959.2023.02.013]
 NI Ke,LI Lei,HUI Jia-yin,et al.Correlation Between the Peripheral Blood miR-21 Expression Level and Aggressive Behavior in Patients with Schizophrenia[J].Journal of Medical Information,2023,36(21):65.[doi:10.3969/j.issn.1006-1959.2023.02.013]

更新日期/Last Update: 1900-01-01